Covalon Technologies (COV) Q4 2024 earnings summary

Executive summary

• Achieved third consecutive quarter of over 30% growth and positive net income and EBITDA, reversing a nine-quarter loss streak, with Q4 revenue of $8.9M and FY2024 revenue of $31.2M, up 17% year-over-year.

• Full-year net income was $2.7M, a turnaround from a $4.5M loss the prior year, and EPS improved to $0.11 from -$0.29.

• Cash position nearly doubled to $16.7M, with zero debt, supported by strong free cash flow and warrant exercises.

• Share price more than tripled over the past year, reflecting operational turnaround and valuation acceleration.

• Focused on foundational advancements, commercial organization transition, and a shift toward a more predictable, high-growth business model.

Financial highlights

• Q4 revenue was $8.9M, up 29% year-over-year; full-year revenue reached $31.2M, up 17%.

• Q4 gross margin improved to 60.2% (+1,830 bps YoY); full-year gross margin was 61% (+670 bps YoY).

• Adjusted EBITDA for Q4 was $1.1M; full-year Adjusted EBITDA reached $4.8M, a $7.5M improvement from 2023.

• Net income for Q4 was $613K (vs. -$2.88M prior year); full-year net income was $2.7M (vs. -$4.5M prior year).

• Operating expenses decreased by over $2M despite nearly $5M revenue growth.

Outlook and guidance

• Management sees a significant multi-year growth opportunity, especially in U.S. medical consumables, and remains focused on aggressive growth, operational efficiency, and innovation.

• Key 2025 priorities include commercial advancement, market development, operational optimization, and business development.

• No forward-looking guidance provided, but management anticipates continued growth and impact in 2025 and beyond.